Open Access

Antithrombin III (AT) and recombinant tissue plasminogen activator (R-TPA) used singly and in combination versus supportive care for treatment of endotoxin-induced disseminated intravascular coagulation (DIC) in the neonatal pig

  • Rachel Davis-Jackson1Email author,
  • Hernan Correa2,
  • Ronald Horswell3,
  • Halina Sadowska-Krowicka4,
  • Kathleen McDonough5,
  • Chittaranjan Debata6,
  • Renee' Gardner6 and
  • Duna Penn6
Thrombosis Journal20064:7

DOI: 10.1186/1477-9560-4-7

Received: 30 June 2005

Accepted: 18 May 2006

Published: 18 May 2006

Abstract

Background

Disseminated intravascular coagulation (DIC) is a pathological disturbance of the complex balance between coagulation and anticoagulation that is precipitated by vascular injury, acidosis, endotoxin release and/or sepsis and characterized by severe bleeding and excessive clotting. The innately low levels of coagulation factors found in newborn infants place them at extremely high risk for DIC. Anecdotal reports suggest that either anticoagulant or fibrinolytic therapy may alleviate some of the manifestations of DIC. To test the hypothesis that replacement of both anticoagulants and fibrinolytics may improve survival and outcome better than either single agent or supportive care alone, we utilized a neonatal piglet model of endotoxin-induced DIC.

Methods

DIC was induced in twenty-seven neonatal pigs (7 to 14 days of age) by intravenous administration of E. coli endotoxin (800 μg/kg over 30 min). The piglets were divided into 4 groups on the basis of treatment protocol [A: supportive care alone; B: Antithrombin III (AT, 50 μg/kg bolus, 25 μg/kg per hr continuous infusion) and supportive care; C: Recombinant Tissue Plasminogen Activator (R-TPA, 25 μg/kg per hr continuous infusion) and supportive care; D: AT, R-TPA and supportive care] and monitored for 3 primary outcome parameters (survival time, macroscopic and microscopic organ involvement) and 4 secondary outcome parameters (hematocrit; platelet count; fibrinogen level; and antithrombin III level).

Results

Compared with supportive care alone, combination therapy with AT and R-TPA resulted in a significant improvement of survival time, hematocrit, AT level, macroscopic and microscopic organ involvement, p < 0.05. Compared with supportive care alone, R-TPA alone significantly reduced macroscopic organ involvement and AT alone increased AT levels.

Conclusion

The findings suggest that combining AT, R-TPA and supportive care may prove more advantageous in treating the clinical manifestations of DIC in this neonatal pig model than either single modality or supportive care alone.

Background

DIC is a combination of enhanced thrombosis and decreased fibrinolysis. It is precipitated by some underlying disorder, e.g. sepsis, that results in production and release of proinflammatory cytokines. These activate the coagulation cascade, inhibit physiologic anticoagulant pathways, and depress fibrinolysis, resulting in enhanced fibrin formation and impaired fibrin removal [1].

Initiated by either contact phase or tissue factor activation, the coagulation cascade is a set of reactions involving multiple coagulation factors and cofactors [2] that result in the generation of thrombin which acts on the fibrin polymer to produce a fibrin clot [3]. This process is subject to regulation by intrinsic inhibitors, e.g. AT and protein C. One of the major inhibitors of coagulation is AT. It rapidly binds and inactivates thrombin and factor Xa by forming thrombin-antithrombin and factor Xa-antithrombin complexes [4]. Protein C is a vitamin K-dependent inactive enzyme precursor that when activated, proteolytically inactivates the activated factors VIII and V by way of cleavage reactions.[5]

The fibrinolytic pathway is a set of reactions involving fibrinolytic factors and cofactors [2] that clear unneeded fibrin from intravascular and extravascular sites [4]. During fibrinolysis, plasminogen is cleaved by tissue plasminogen activator (TPA) or urokinase-type plasminogen activator to form plasmin that lyses the fibrin clot, releasing fibrin degradation products. During DIC, thrombin generation proceeds via the extrinsic tissue factor/factor VIIa route with simultaneous depression of inhibitory mechanisms, such as AT and Protein C [1] and enhanced inhibition of fibrinolysis by plasminogen activator inhibitor (PAI-1) [6].

Neonates are innately predisposed to acquire DIC due to altered levels of coagulation and fibrinolytic proteins that differ markedly from those in adults [5, 7]. In neonates, AT levels are within the concentration range at which spontaneous thromboses could occur in adults. Protein C and Protein S are reduced at birth to 30% of adult plasma concentrations and remain decreased during the first weeks of life [5]. In addition, differences in plasma concentrations of fibrinolytic proteins may also contribute to predisposition for DIC [7]. At birth, newborn plasminogen levels are 58% of adult concentrations while plasma concentrations of PAI-1 and TPA are approximately twice adult concentrations and decrease to adult plasma concentration values by day 5 of life [5]. Impaired fibrin degradation, due to high circulating levels of PAI-1, contributes to enhanced intravascular fibrin deposition [1].

Furthermore, sepsis, a major risk factor for DIC, occurs in infants with an incidence of 1 to 5 per 1,000 live births. Mortality is high in the septic neonate, up to 50% for early onset-sepsis [8]., and survivors often exhibit increased morbidity. Hypercoagulability is often seen during sepsis. Fibrin deposition leads to microvascular and less frequently, large vessel thrombosis with impaired perfusion and subsequent organ damage [9]. These microvascular thrombi in various organs contribute to the development of multiorgan failure [4]. Neonates surviving an episode of DIC may be left with the burden of such sequelae and diminished quality of life. For these reason, effective therapy for DIC would have tremendous impact.

Unfortunately, the therapy for DIC in the neonate is by no means optimal. The current mainstay of therapy is "treatment of the underlying illness" and supportive care. The efficacy of coagulant replacement therapy in the overall treatment of DIC in the septic infant is controversial. Gross, et al. reviewed a group of infants with sepsis and DIC and concluded that successful outcome depended on treatment of the underlying illness and that therapy directed toward the coagulopathy did not result in improved outcomes [10]. However, Gross used a nonspecific global approach by administering fresh frozen plasma to replace diminished coagulation factors.

Specific treatment directed toward either the coagulation or fibrinolytic derangement has occasionally been attempted. Previous studies suggest that a unilateral approach to the coagulation or fibrinolytic deficiencies may be of some benefit (Table 1). Most of the human studies were performed in children or adolescents. Because of ethical concerns, controlled studies with neonates are difficult and limited data are available. The animal studies performed so far have focused mainly on correction of anticoagulation defects, although Munoz, et al. addressed both the anticoagulation and fibrinolytic abnormality using a rabbit model [11]. The current study utilizes a newborn piglet model of endotoxin-induced DIC to mimic sepsis and examines the effect of replacing AT and R-TPA singly and in combination. Both are currently available for human use. The newborn piglet was chosen as it is the closest non-primate animal model of the human neonate with respect to anatomy, physiology, biochemistry and metabolism [12]. The hemostatic system in the pig is very similar to that of the human adult[13, 14]. Table 2 compares normal coagulation values with reference intervals for the pig and human [15]. Massicotte, et al. considered the newborn piglet to be a suitable model for investigation of specific hemorrhagic and thrombotic problems in the newborn [13].
Table 1

Summary of selected therapeutic approaches using replacement of specific anticoagulation and fibrinolytic proteins to treat DIC. This table is based on a PubMed search using the key words: "Disseminated Intravascular Coagulation", "Therapy for DIC", "Animal experimentation on DIC" and "Neonate or Newborn." A representative selection was chosen from a total of 98 papers in the period 1970 to 2005 to give an overview of the literature on this subject.

Subject

Mortality Rate

N

Therapeutic Factor

Provoking Factor

Outcome

Reference

Coagulation Pathway

Children

not addressed

4

Protein C

meningococcemia

reversed organ dysfunction

[16]

Infants, adolescents

25%

8

Protein C

meningococcemia

restored micro-circulation

[17]

Children 1 mo-5 yr

17%

6

AT

sepsis, carcinoma, Reye's

normalized coagulation studies

[18]

Newborns

40%

10

AT, heparin

sepsis

improved coagulation

[22]

Child

100%

1

AT, Protein C

Unknown, ARDS

stopped bleeding

[19]

Baboons

67–100%

3

Protein C

E. coli organisms

prevented coagulopathy, lethal effects

[25]

Adult pigs

not addressed

16

AT

E. coli endotoxin

Improved MAP, SVR

[23]

Guinea pigs

0% with Tx

58

Antithrombin Concentrate & LMWH

S. aureus isolates

Decreased fibrin deposits, improved survival

[26]

Adult pigs

Not addressed

 

AT

LPS

decreased DIC, improved survival

[21]

Adult pigs

Not addressed

21

AT

LPS

reduced effusion, edema

[27]

Newborn and 3 wk old piglets

Not Addressed

>>16/age group & dose

Heparin

125I-Fibrinogen

↑ AT conc. Improved the antithrombotic effects of heparin

[28]

Fibrinolytic Pathway

Infant, 4 mo

0%

N 1

R-TPA

meningococcemia

improved organ perfusion, cardiac performance

[24]

Infants

0%

2

R-TPA

Meningococcemia

Improved micro-circulation

[20]

Combined Coagulation and Fibrinolytic Pathways

Adult rabbits

70 → 40% R-TPA alone, 70 → 0% both factors

N

R-TPA, R-hirudin

endotoxin

Improved hemostatic markers, decreased fibrin deposits

[11]

Legend: ARDS Adult respiratory distress syndrome

E. Coli Escherichia Coli

kg kilogram

LMWH Low molecular weight heparin

MAP Mean Arterial Pressure

SVR Systemic Vascular Resistance

S. aureus Staphylococcal aureus

Tx Therapy

R-hirudin Recombinant Hirudin

N Subject number

Table 2

Porcine and Human Coagulation Values and Reference Ranges [7,15,5]

 

Porcine Juvenile

Human Premature Neonate

Human Term Neonate

Human Adult

Parameter

Mean ± SD

₤ Mean ± SD Range (mean)

₤ Mean ± SD Range (mean)

Mean ± SD

Hct %

28.89 ± 3.88

₤ 60 ± 8

₤ 61 ± 7

41 ± 3.0

Plt G/L

407.32 ± 121.24

10.6–16.2 (13.0)

10.1–15.9 (13.0)

265.0 ± 57.5

AT %

100.89 ± 11.43

0.14–0.62 (0.38)

0.39–0.87 (0.63)

100.0 ± 10.0

Fib mg/100 ml

357.44 ± 88.43

1.5–3.73 (2.43)

1.67–3.99 (2.83)

285.0 ± 47.5

The major goal of this experiment was to test the hypothesis that replacement of both AT and R-TPA would improve survival and decrease the severity of the disease in the neonate better than either single agent or supportive care alone.

Methods

Twenty-seven newborn piglets, 7–14 days old, were randomly divided into four groups on the day of experiment (Table 3). Each group received supportive care with or without some other form of therapy. Supportive care included maintenance intravenous fluids (5% dextrose and 1/2 normal saline, 150 ml/kg/day); respiratory support (tidal volume 15 ml/kg, ventilator rate 20/min, FiO2 1.0); volume expansion for decreased mean blood pressure (BP < 30 mm Hg), or central venous pressure (CVP < 5 cm H2O) and/or urine output (< 1 ml/kg/hr for more than 2 hours); and dopamine/dobutamine administration (5–15 μg/kg per min) for hypotension unresponsive to a cumulative volume expansion of 60 ml/kg. Group A received supportive care only. Group B received AT (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion) and supportive care. Group C received R-TPA (0.025 mg/kg/hr) and supportive care. Group D was the combination therapy group receiving AT, R-TPA and supportive care.
Table 3

Description of study groups.

Group

(n)

AT

R-TPA

Supportive Care

A (control)

9

No

No

Yes

B

6

Yes

No

Yes

C

6

No

Yes

Yes

D

6

Yes

Yes

Yes

Legend: AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr).

After anesthesia was induced with intravenous pentobarbital, each piglet was surgically equipped with an endotracheal tube for assisted ventilation, as well as central venous, arterial and bladder catheters. After an initial stabilization period of one hour, DIC was induced by injecting Escherichia Coli endotoxin (800 μg/kg over 30 min). Two animals in Group A received 1000 μg/kg. As there were no differences in response noted between them and the 7 animals that received 800 μg/kg of endotoxin, they were included in the analysis. Vital signs and urinary output were continuously monitored. Blood pressure, amount of fluid resuscitation and pressor use were measured to assess our success in maintaining mean BP greater than 30 mm Hg, as per protocol. Serial hematologic and coagulation studies were performed (at 30 min, 1, 2, 4, 6 and 7 hours). After 7 hours, surviving animals were euthanized by exsanguination under deep anesthesia.

The dosages of endotoxin, AT and R-TPA were selected on the basis of review of the literature and pilot studies. Based on studies by Dickenite et al. (24) and Taylor et al. (21) initial doses of endotoxin ranging from 66 to 600 μg/kg were tested. Since these dosages did not produce hemotologic evidence of DIC, the dosage was increased to 800 micrograms/kg which gave definite and reproducible hematologic evidence of DIC and manageable hypotension in most cases.

The dosage for R-TPA was based on studies by Munoz, et al. (15). As doses of R-TPA of 0.2 mg/kg/hr and 0.1 mg/kg/hr were associated with ascites and hemorrhage in various organs, the dosage was decreased to 0.025 mg/kg/hr.

Finally, the AT dosage was derived from Dickenite et al.(23) and tested in pilot studies of AT dosages ranging from 1 unit/kg/hr to 73 units/kg/hr with and without and boluses ranging from 5 to 250 units/kg. The lower dosages had no effects upon clinical condition and AT levels. The highest doses improved AT levels, but were associated with increased hemorrhage. Eventually the dose of 50 units/kg bolus and 25 units/kg/hr continuous drip was chosen to maximize beneficial effect and minimize side effects.

At necropsy, macroscopic organ involvement was subjectively rated by the researchers for visible evidence of hemorrhage in the right or left kidney, heart and liver. Scores of 0–4 were given denoting the number of organs with visible evidence of macroscopic hemorrhage. Tissue samples were collected for histological examination.

Piglet kidney sections were stained with hematoxylin and eosin and evaluated microscopically in a blinded fashion by a single pathologist, Dr. Hernan Correa. All samples were assigned values on a scale from 0–5 (0: no involvement; 1: minimal; 2: mild; 3: moderate; 4: moderately severe; and 5: severe) for two different categories: congestion which was defined by presence and amount of fluid accumulation; hemorrhage which was defined by evidence and degree of bleeding. In addition, thrombosis was rated by presence (+1) or absence (0) of clot formation.

Primary outcome parameters included survival time, macroscopic and microscopic organ involvement and secondary outcome parameters included hematocrit; platelet count; fibrinogen level; and AT level. Blood pressure was a clinical variable measured to assess our success in maintaining mean BP greater than 30 mm Hg, as per protocol. Each treatment factor (AT, R-TPA), was tested at two levels. The first level compared the factor alone against supportive care alone and the second level compared the combined factors against supportive care alone. Statistical analysis of the data was undertaken using matched pair t-tests to compare baseline to follow-up changes for platelets, fibrinogen, AT, blood pressure and hematocrit level within each of the four groups. A permutation procedure was used to calculate significance levels due to non-normality and heteroskedasticity across treatment groups for blood pressure. A permutation test was also used to compare groups on number of organs displaying macroscopic organ involvement. Survival time across groups was compared using a survival model assuming exponentially distributed survival times with survival time censored at seven hours. P-values are from one-way statistical tests and are not adjusted for multiple testing, as these analyses are considered exploratory rather than confirmatory. All analyses were done using Stata 8.2.

This project was reviewed and approved by the Louisiana State University Institutional Animal Care and Use Committee.

Results

Clinical parameters

Blood pressure

Mean blood pressures fell (P < 0.0002) after the administration of endotoxin (Table 4). The average change from baseline to follow-up for BP was statistically analyzed for each group. There were no significant differences among the groups. Table 5 demonstrates the amount of fluids and pressors administered to each group, following parameter protocols for fluid resuscitation and pressor usage. The apparent incongruity noted in Group A requiring the least amount of resuscitation is more than likely secondary to the shortened survival time of these piglets.
Table 4

Changes in blood pressure in anesthetized piglets before and after induction of DIC by intravenous administration of endotoxin.

Mean Blood Pressure ± SD (mm Hg)

P-Value*

Group

Basal

Follow-up

Δ

B vs.

C vs.

D vs.

A: Supportive care

74 ± 11

32 ± 23

-42 ± 26

0.238

0.195

0.118

B: AT

70 ± 17

25 ± 13

-45 ± 26

 

0.970

0.382

C: R-TPA

70 ± 15

23 ± 13

-47 ± 6

  

0.375

D: AT + R-TPA

65 ± 13

29 ± 4

-36 ± 14

   

Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. * P-values are based on statistical analysis of the average change (Δ) from baseline to follow-up for BP (paired t-test).

Table 5

Fluid and pressor usage in the 4 groups of piglets following endotoxin administration.

Group

Fluid Volume (ml)

Dopamine

Dopamine + Dobutamine

A

107.8 ± 61.7

33%

33%

B

82.2 ± 34.6

100%

67%

C

83.7 ± 56.8

100%

50%

D

121.7 ± 66.8

100%

83%

* P -values

0.559

0.49

0.528

Legend: Fluid volume is the mean of total volume given in resuscitative measure for that particular group ± the standard deviation. The use of Dopamine and Dobutamine is expressed as percentage of animals in each group that received pressors. *P-values reflect testing for differences across the groups (Fisher's Exact Test).

Survival time

The survival time findings (Fig. 1) support the research hypotheses showing a tendency for improving survival across the groups (A < B = C < D). Mean survival times (± SD) were 4.16 ± 3.10, 4.92 ± 3.23, 5.58 ± 2.25, and 7.00 ± 0.00 hours for Groups A, B, C, and D, respectively. Mean survival time was only significantly different between Groups A and D (P = 0.042), suggesting that the combined effect of AT and R-TPA was greater than either individual effect. However, the small sample size is problematic and limited the power to detect survival time differences statistically. Moreover, censoring survival time at seven hours may have limited detection of variation across the groups. A longer survival time cut-off may have allowed detection of other survival time differences.
https://static-content.springer.com/image/art%3A10.1186%2F1477-9560-4-7/MediaObjects/12959_2005_Article_48_Fig1_HTML.jpg
Figure 1

Survival curve by treatment group of anesthetized piglets following DIC induction by intravenous administration of E. coli endotoxin (800 μg/kg over 30 min). The numbers on the far right of each survival curve indicate the number of surviving animals after 7 hours as a fraction of the original number. Group A: supportive care only (n = 9); Group B: supportive care + AT (antithrombin III) (n = 6); Group C: supportive care + R-TPA (recombinant tissue plasminogen activator) (n = 6); Group D: supportive care + AT + R-TPA (n = 6).

Macroscopic and microscopic organ involvement

The data (Figure 2) suggest that R-TPA and combined therapy reduce macroscopic organ involvement after induction of DIC. Figure 3 demonstrates typical organ involvement. The data shown in Fig. 4 support our research hypothesis that combined therapy with AT and R-TPA results in less microscopic organ involvement than supportive therapy alone.
https://static-content.springer.com/image/art%3A10.1186%2F1477-9560-4-7/MediaObjects/12959_2005_Article_48_Fig2_HTML.jpg
Figure 2

Macroscopic organ involvement after induction of DIC in anesthetized piglets. At necropsy, scores of 0 to 4 were given based on number of organs (right or left kidney, heart and liver) with visible evidence of hemorrhage. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr). Data are expressed as mean ± SD (standard deviation). *P < 0.025, compared with supportive therapy alone.

https://static-content.springer.com/image/art%3A10.1186%2F1477-9560-4-7/MediaObjects/12959_2005_Article_48_Fig3_HTML.jpg
Figure 3

Photograph of right and left kidneys from A) a piglet from Group A that received only supportive care, exhibiting hemorrhages in the renal parenchyma; and B) an animal from Group D that received supportive care, R-TPA and AT. No hemorrhagic changes were seen.

https://static-content.springer.com/image/art%3A10.1186%2F1477-9560-4-7/MediaObjects/12959_2005_Article_48_Fig4_HTML.jpg
Figure 4

Microscopic organ involvement. After staining with hematoxylin and eosin, piglet kidney histology specimens were evaluated microscopically in a blinded fashion by a single pathologist and assigned values on a scale from 0–5 (0: no involvement; 1: minimal; 2: mild; 3: moderate; 4: moderately severe; and 5: severe) for two different categories: congestion and hemorrhage. Thrombosis was rated by presence (+1) or absence (0). AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr). Data are expressed as Mean ± SD (standard deviation). Group A: n = 4; Group B: n = 5; Group C: n = 4; Group D: n = 5. * P < 0.05 compared with supportive care alone.

Hematocrit levels

The average change from baseline to follow-up for hematocrit (Table 6) was statistically analyzed for each group. The pattern of change was consistent with the research hypotheses. Specifically, hematocrit was better preserved in Group D than in Group A (P = 0.003) and tended to be better than in Group C (P = 0.05).
Table 6

Changes in hematocrits of anesthetized piglets before and after induction of DIC by intravenous administration of endotoxin.

Mean Hematocrit ± SD (%)

P-Value*

Group

Basal

Follow-up

Δ

B vs.

C vs.

D vs.

A: Supportive care

26 ± 5

21 ± 8

-5 ± 4

0.155

0.353

0.003

B: AT

28 ± 9

26 ± 9

-2 ± 7

 

0.647

0.115

C: R-TPA

32 ± 5

28 ± 8

-4 ± 7

  

0.050

D: AT + R-TPA

27 ± 5

29 ± 6

2 ± 4

   

Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. * P-values are based on statistical analysis of the average change from baseline to follow-up for hematocrit (paired t-test).

Platelets

The average change from baseline to follow-up in platelet level was analyzed for each group (Table 7). There were no statistically significant differences among the groups although the power was low due to the limited sample size.
Table 7

Changes in platelet count of anesthetized piglets before and after induction of DIC by intravenous administration of endotoxin.

Mean Platelet Count ± SD (× 103/cu. mm)

P-Value*

Group

Basal

Follow-up

Δ

B vs.

C vs.

D vs.

A: Supportive care

532 ± 274

179 ± 192

-353 ± 268

0.105

0.392

0.332

B: AT

574 ± 133

357 ± 134

-217 ± 79

 

0.090

0.775

C: R-TPA

543 ± 74

207 ± 85

-336 ± 130

  

0.407

D: AT + R-TPA

666 ± 203

408 ± 274

-258 ± 262

   

Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. * P-values are based on statistical analysis of the average change from baseline to follow-up for platelet count (paired t-test).

Fibrinogen level

The average change from baseline to follow-up (Table 8) was analyzed for each group. There were no significant differences found.
Table 8

Changes in fibrinogen levels of anesthetized piglets before and after induction of DIC by intravenous administration of endotoxin.

Mean Fibrinogen Level ± SD (mg/dl)

P-Value*

Group

Basal

Follow-up

Δ

B vs.

C vs.

D vs.

A: Supportive care

144 ± 23

67 ± 27

-77 ± 34

0.102

0.786

0.571

B: AT

156 ± 26

104 ± 32

-52 ± 33

 

0.055

0.823

C: R-TPA

149 ± 31

60 ± 43

-89 ± 26

  

0.307

D: AT + R-TPA

157 ± 36

85 ± 33

-72 ± 52

   

Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. * P-values are based on statistical analysis of the average change from baseline to follow-up for fibrinogen level (paired t-test).

AT level

The data (Fig. 5) clearly demonstrate a positive effect of AT administration upon post-endotoxin AT levels and support the research hypothesis.
https://static-content.springer.com/image/art%3A10.1186%2F1477-9560-4-7/MediaObjects/12959_2005_Article_48_Fig5_HTML.jpg
Figure 5

Antithrombin III levels in anesthetized piglets receiving endotoxin. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr). Data are expressed as mean ± SD (standard deviation). * P < 0.005 compared with supportive care alone; &P < 0.035, compared with Group C (R-TPA alone)

Discussion

DIC is a life-threatening disease with serious mortality and morbidity. Controversy exists concerning the efficacy of various treatment modalities using coagulation factor replacement [16].

Most previously published studies [1720] used a monotherapeutic approach directed at either the anticoagulation or fibrinolytic derangement and were performed in children, adolescents or adults. There have been very few reports in the literature concerning such therapies in the neonate [20, 22]. Yet, neonates, and especially premature infants, are at increased risk for DIC due to developmental differences in their levels of coagulation and anticoagulation factors at birth [4]. This study explored the efficacy of a dual anticoagulation and fibrinolytic agent replacement therapy in the newborn piglet model of DIC.

Although hampered by a small sample size that limited the power to demonstrate statistical significance, our study results from the first level of analysis, i.e. factor alone compared with supportive care, showed a trend toward improved survival and less severe hematologic and coagulation system derangements that are comparable with past studies. Dickneite, et al. [21] demonstrated that AT administered to adult pigs in porcine septic shock decreased DIC and improved survival. Von Kries, et al. [22] reported that AT administration improved the coagulation derangement in 10 newborns with sepsis. In contrast to Fourier, et al [23] who reported improved mean arterial pressure and systemic vascular resistance when AT was used after E. Coli endotoxin was administered to adult pigs, we found no beneficial effect of AT on blood pressure in our piglets. This may reflect differences in cardiovascular response between neonatal and adult responses in the pig, but could also just be due to the small numbers and low power of our study.

DIC affects not only the anticoagulation system, but also the fibrinolytic system. Yet, data on the fibrinolytic approach are limited. R-TPA has been used in 3 infants with DIC due to meningococcemia [20, 24] with improved perfusion and cardiac performance. Only one study [11], performed in an adult rabbit model of DIC, utilizing R-TPA and R-hirudin, addressed both anticoagulation and fibrinolytic abnormalities and reported improved hemostatic markers and decreased fibrin deposits. To our knowledge, our study represents the first attempt to utilize dual treatment of DIC in the susceptible neonate or animal model representative of the neonate. Our major goal was to determine if addressing both sides of the problem in the neonatal pig after endotoxin-induced DIC could improve survival and outcome.

Conclusion

Our very preliminary data suggests that combined therapy with AT and R-TPA improved survival, degree of macroscopic and microscopic organ involvement and hematocrit in this piglet model of endotoxin-induced DIC compared with supportive care alone. We were unable to demonstrate such beneficial effects with the use of single agent therapies, but this may be due to the small sample size resulting in low power. AT administration increased AT levels similarly whether used as a single agent or in combination with R-TPA. Yet, the beneficial effect on survival and organ involvement was only significant in the combined therapy group suggesting an additive effect of the fibrinolytic component. No adverse effects, e.g. exacerbation of bleeding or clot formation, were found using these dosages in this model. Further studies with larger numbers of subjects are obviously needed to confirm these findings and to assess the true safety and efficacy of the combined therapeutic approach. However, the findings are encouraging and may point the way to a novel therapeutic approach to improve mortality and the quality of life for neonates that survive an episode of DIC.

Declarations

Acknowledgements

The authors thank Lisa Dayan, Roy Dubose and Roopa Gopal for their expert technical assistance and Genentech for the contribution of R-TPA used in this experiment. The authors also thank Mary Defoe for her expertise in literature searches.

Authors’ Affiliations

(1)
(La.), Louisiana State University Health Sciences Center – Earl K. Long Medical Center
(2)
New Orleans Children's Hospital Dept. of Pathology, Louisiana State University Health Sciences Center
(3)
Pennington Biomedical Research Center, Louisiana State University Health Sciences Center
(4)
New Orleans, Dept. of Pediatrics, Research Institute for Children, Louisiana State University Health Sciences Center
(5)
New Orleans, Dept. of Physiology, Louisiana State University Health Sciences Center
(6)
New Orleans, Dept. of Pediatrics, Children's Hospital, Louisiana State University Health Sciences Center

References

  1. Levi MJE, van der Poll T: New Treatment strategies for disseminated intravascular coagulation based on current understanding of pathophysiology. Annals of Medicine 2004, (36):41-49. 10.1080/07853890310017251
  2. Tapper HHHB: Modulation of hemostatic mechanisms in bacterial infectious diseases. 2000, 96(7):2329-2337.Google Scholar
  3. Esmon CT: Blood Coagulation, in Nathan and Oski's Hematology of Infancy and Childhood. Edited by: Nathan DGaO, Stuart H. W.B Saunders Co: Philadelphia; 1998:1531-1557.Google Scholar
  4. de Jonge ELM, Christiaan SP, van Deventer SJH: Current Drug Treatment Strategies for Disseminated Intravascular Coagulation. Drugs 1998, 55(6):767-777. 10.2165/00003495-199855060-00004View ArticlePubMedGoogle Scholar
  5. Edstrom C, Christensen RD, Andrew M: Developmental Aspects of Blood Hemostasis and Disorders of Coagulation and Fibrinolysis in the Neonatal Period, in Hematologic Problems of the Neonate. Edited by: Christensen RD. W.B. Saunders Co.: Philadelphia; 2000:239, 242, 243-257.Google Scholar
  6. Kreuz WVA, Fischer D, Schlosser R, Volk WR, Ettingshausen LE: Neonatal Sepsis. A Challenge in Hemostaseology. Seminars in Thrombosis and Hemostasis 1999, 25(6):531-534.View ArticlePubMedGoogle Scholar
  7. Andrew MPB, Johnston M: Development of the coagulation system in the healthy premature infant. Blood Coagulation and Fibrinolysis 1988, 72: 1651.Google Scholar
  8. Fanaroff AAMR: The Immune System/The Blood and Hematopoietic System, in Neonatal-Perinatal Medicine. In Diseases of the fetus and infant. Edited by: Fanaroff AAMR. Mosby: St. Louis, MO; 1997:717-1244.Google Scholar
  9. Lilleyman JHI, Blanchette V: Pediatric Hematology, in Pediatric Hematology. Saunders 1999, 631-633.Google Scholar
  10. Gross SJFH: Controlled study of treatment of disseminated intravascular coagulation in the neonate. The Journal of Pediatrics 1982, 100(3):445-448. 10.1016/S0022-3476(82)80457-5View ArticlePubMedGoogle Scholar
  11. Munoz MCMR, Hermida J, Orbe J, Paramo JA, Rocha E: Effect of the administration of recombinant hirudin and/or tissue plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. British Journal of Haematology 1999, 105: 117-122. 10.1111/j.1365-2141.1999.01298.xView ArticlePubMedGoogle Scholar
  12. Swindle M, Hand MS, Phillips RW, Fettman MJ, Chandrasena LG: Porcine Model in surgical research/Endotoxemic swine as a model for the metabolic response to sepsis, in Swine in Biomedical Research. Edited by: Tumbleson M. Plenum Publishing Corp: New York; 1986:235-453.Google Scholar
  13. Massicotte P, Mitchell L, Andrew M: A comparative study of coagulation systems in newborn animals. Pediatr Res 1986, 20(10):961-5.View ArticlePubMedGoogle Scholar
  14. Federation of American Societies for Experimental Biology and American Physiological Society (1887-). Federation proceedings, Federation of American Societies for Experimental Biology [Bethesda, Md., etc.] 46v.
  15. Velik-Salchner C, Schnurer C, Fries D, Mussigang PR, Moser PL, Streif W, Kolbitsch C, Lorenz IH: Normal values for thrombelastography (ROTEM(R)) and selected coagulation parameters in porcine blood. Thromb Res 2006, 117(5):597-602. 10.1016/j.thromres.2005.05.015View ArticlePubMedGoogle Scholar
  16. Rivard GEDM, Farrell C, Schwarz HP: Treatment of purpura fulminans in meningococcemia with protein C concentrate. Journal of Pediatrics 1995, 646-651.Google Scholar
  17. Ettingshausen CEVA, Beeg T, Schneider W, Jager G, Kreuz W: Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans. Seminars in Thrombosis and Hemostasis 1999, 25(6):537-541.View ArticlePubMedGoogle Scholar
  18. Hanada TAT, Takita H: Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children. The American Journal of Pediatric Hematology/Oncology 1985, 7(1):3-8.PubMedGoogle Scholar
  19. Favier RDA, Belhocine R, Ankri A, Costil J, de Moerloose P: Simultaneous administration of antithrombin III and protein C concentrates for the treatment of a devastating coagulopathy in a child. Hematology and Cell Therapy 1998, 40: 67-70.PubMedGoogle Scholar
  20. Zenz WMW, Gallistl S, Zobel G, Grubbauer HM: Recombinant Tissue Plasminogen Activator Treatment in Two Infants With Fulminant Meningococcemia. Pediatrics 1995, 96(1):144-147.PubMedGoogle Scholar
  21. Dickneite GLB: Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999, (19):1566-1572.
  22. Kries RVSH, Gobel U: Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. European Journal of Pediatrics 1985, 144: 191-194. 10.1007/BF00451912View ArticleGoogle Scholar
  23. Fourrier FJM, Tournoys A, Gosset P, Mangalaboyi J, Chopin C: Effects of a combined Antithrombin III and Protein C supplementation in porcine acute endotoxic shock. Shock 1998, 10(5):364-370.View ArticlePubMedGoogle Scholar
  24. Auito LTBS, Cohen PS, Boxer RA: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Critical Care Medicine 1997, 25(6):1079-1082. 10.1097/00003246-199706000-00028View ArticleGoogle Scholar
  25. Taylor FBCA Jr, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE, Protein C: Prevents the Coagulopathic and Lethal Effects of Escherichia coli Infusion in the Baboon. Journal of Clinical Investigations 1987, 79: 918-925.View ArticleGoogle Scholar
  26. Kessler CMTZ, Jacobs HM, Szymanski LM: The Suprapharmacologic Dosing of Antithrombin Concentrate for Staphylococcus Aureus-Induced Disseminated Intravascular Coagulation in Guinea Pigs: Substantial Reduction in Mortality and Morbidity. Blood Coagulation and Fibrinolysis 1997, 89(12):4393-4401.Google Scholar
  27. Dickneite G, Kroez M: Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk of bleeding. Blood Coagulation and Fibrinolysis 2001, 12(6):459-467. 10.1097/00001721-200109000-00006View ArticlePubMedGoogle Scholar
  28. Schmidt BMRB, Ofosu F, Brooker L, Hirsh J, Andrew M: Antithrombotic Properties of Heparin in a Neonatal Piglet Model of Thrombin-Induced Thrombosis. Thrombosis and Haemostasis 1988, 60(2):289-292.PubMedGoogle Scholar

Copyright

© Davis-Jackson et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement